Deep Sequencing of B Cell Receptor Repertoires From COVID-19 Patients Reveals Strong Convergent Immune Signatures

Other authors

Institut Català de la Salut

[Galson JD, Schaetzle S, Kilpatrick GJ] Alchemab Therapeutics Ltd, London, United Kingdom. [Bashford-Rogers RJM] Alchemab Therapeutics Ltd, London, United Kingdom. Wellcome Centre for Human Genetics, Oxford, United Kingdom. [Raybould MIJ, Kovaltsuk A] Oxford Protein Informatics Group, Department of Statistics, University of Oxford, Oxford, United Kingdom. [Seoane J] Translational Research Program, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain

Vall d'Hebron Barcelona Hospital Campus

Publication date

2021-09-09T06:30:47Z

2021-09-09T06:30:47Z

2020-12-15



Abstract

Repertori de cèl·lules B; SARS-CoV-2; Anticòs


Repertorio de células B; SARS-CoV-2; Anticuerpo


B-cell repertoire; SARS-CoV-2; Antibody


Deep sequencing of B cell receptor (BCR) heavy chains from a cohort of 31 COVID-19 patients from the UK reveals a stereotypical naive immune response to SARS-CoV-2 which is consistent across patients. Clonal expansion of the B cell population is also observed and may be the result of memory bystander effects. There was a strong convergent sequence signature across patients, and we identified 1,254 clonotypes convergent between at least four of the COVID-19 patients, but not present in healthy controls or individuals following seasonal influenza vaccination. A subset of the convergent clonotypes were homologous to known SARS and SARS-CoV-2 spike protein neutralizing antibodies. Convergence was also demonstrated across wide geographies by comparison of data sets between patients from UK, USA, and China, further validating the disease association and consistency of the stereotypical immune response even at the sequence level. These convergent clonotypes provide a resource to identify potential therapeutic and prophylactic antibodies and demonstrate the potential of BCR profiling as a tool to help understand patient responses.


MR is supported by an Engineering and Physical Sciences Research Council (EPSRC) and Medical Research Council (MRC) grant (EP/L016044/1). AK is supported by a Biotechnology and Biological Sciences Research Council (BBSRC) grant (BB/M011224/1).

Document Type

Article


Published version

Language

English

Publisher

Frontiers Media

Related items

Frontiers in Immunology;11

https://doi.org/10.3389/fimmu.2020.605170

Recommended citation

This citation was generated automatically.

Rights

Attribution 4.0 International

http://creativecommons.org/licenses/by/4.0/

This item appears in the following Collection(s)